Ataluren for Nonsense Mutation in CDKL5 and Dravet Syndrome

• ClinicalTrials.gov Identifier: NCT02758626
• Recruitment Status: Active, not recruiting
• First Posted: May 2, 2016
• Last Update Posted: October 23, 2020
• Sponsor: NYU Langone Health
• Collaborator: PTC Therapeutics
• Information provided by (Responsible Party): NYU Langone Health

Study Description

Brief Summary:

This is a phase 2, crossover study of Ataluren for the treatment of nonsense mutation Dravet syndrome or cyclin-dependent kinase-like 5 (CDKL5) deficiency, resulting in drug-resistant epilepsy. Patients will receive 12 weeks of ataluren or placebo during each treatment period. Treatment Period 1 will be followed by a 4-week Washout Period. Based on ataluren PK and pharmacodynamic data, the 4-week washout period is deemed an appropriate length of time to eliminate any ataluren drug effects. Following the Washout Period, patients will crossover to receive the opposite treatment during Treatment Period 2 as follows: Patients receiving ataluren during Treatment Period 1 will receive placebo during Treatment Period 2. Patients receiving placebo during Treatment Period 1 will receive ataluren during Treatment Period 2.

Condition or disease	Intervention/treatment	Phase
Epilepsy	Drug: ataluren; Drug: Placebo	Phase 2

Detailed Description:

Investigators will try to characterize the safety profile of ataluren in patients with CDKL5 or Dravet syndrome resulting from a nonsense mutation and evaluate changes in convulsive and/or drop seizure frequency from Baseline following ataluren treatment in patients with CDKL5 or Dravet syndrome resulting from a nonsense mutation. Investigators will measure changes in minor seizure types (absence, myoclonic, complex partial/focal dyscognitive) following ataluren treatment in patients with CDKL5 or Dravet syndrome resulting from a nonsense mutation and changes from Baseline in cognitive, motor, and behavioral function as well as QOL following ataluren treatment in patients with CDKL5 or Dravet syndrome resulting from a nonsense mutation.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 16 participants
• Allocation: Randomized
• Intervention Model: Crossover Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: A Phase 2 Randomized, Double-Masked Placebo-Controlled Crossover Safety and Tolerability Study of Ataluren for Drug Resistant Epilepsy in Patients With Nonsense Mutation CDKL5 or Dravet Syndrome
• Study Start Date: November 2016
• Estimated Primary Completion Date: January 2021
• Estimated Study Completion Date: March 2021

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: Ataluren Followed By Placebo; Cross Over Design: Treatment Period 1 with Ataluren (Week 0/Day 1 to Week 12), Washout Period (Week 12 to Week 16), crossover to Placebo Treatment Period 2 (Week 16 to Week 28), and Follow-up (Week 28 to Week 32).	Drug: ataluren; Powder formulation; Other Name: PTC124; Drug: Placebo; Powder formulation
Active Comparator: Placebo Followed by Ataluren; Treatment Period 1 with Placebo (Week 0/Day 1 to Week 12), Washout Period (Week 12 to Week 16), crossover to Treatment Period 2 with Ataluren(Week 16 to Week 28).	Drug: ataluren; Powder formulation; Other Name: PTC124; Drug: Placebo; Powder formulation

Outcome Measures

Primary Outcome Measures :

1. Number of adverse events and serious adverse events related to ataluren [ Time Frame: Baseline to 3 months ]
2. Number of adverse events and serious adverse events related to ataluren [ Time Frame: 3 months to 6 months ]
3. Number of adverse events and serious adverse events related to ataluren [ Time Frame: 6 months to 1 year ]

Secondary Outcome Measures :

1. Seizure frequency from baseline after ataluren treatment in patients w/ CDKL5 or Dravet from daily seizure diary. [ Time Frame: Baseline, 3 months, 6 months, and 1 year ]

Other Outcome Measures:

1. Change from baseline in cognitive behavior measured by Behavior Assessment System for Children [ Time Frame: Baseline, 3 months and 6 months ]
   Clinical and adaptive measures of personality and behavior using the Behavior Assessment System for Children: Third Edition (Sabaz 2003)
2. Quality of Life (QOL) as assessed by the Quality of Life in Childhood Epilepsy (QOLCE) (Sabaz 2003) [ Time Frame: Baseline, 3 months and 6 months ]

Eligibility Criteria

• Ages Eligible for Study: 2 Years to 12 Years (Child)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Age ≥ 2 years old and ≤ 12 years old, male or female, at Week 0 (at time informed consent/assent is signed)

2. Documentation of a diagnosis of Dravet syndrome or CDKL5 deficiency resulting from a nonsense mutation in 1 allele, as evidenced by medical records, genetic testing, and the following clinical feature:

   a. Failure to control seizures despite appropriate trial of 2 or more AEDs at therapeutic doses

3. Between 1 to 3 baseline AEDs at stable doses for a minimum for 4 weeks prior to the Baseline visit

   a. Vagus nerve stimulator (VNS), ketogenic diet, and modified Atkins diet do not count towards this limit but must be unchanged for 3 months prior to enrollment (Baseline).

4. VNS must be on stable settings for a minimum of 3 months prior to the Baseline visit
5. If on ketogenic or modified Atkins diet, must be on stable ratio for a minimum of 3 months prior to the Baseline visit
6. Written consent obtained from the patient or patient's legal representative must be obtained prior to performing any study procedures
7. Minimum of 6 convulsive or drop seizures with duration > 3 seconds over the 4 weeks of diary screening prior to randomization and ≥ 6 convulsive or drop seizures with duration > 3 seconds during the 4 weeks from Screening to Baseline.

Exclusion Criteria:

1. Patient is < 2 years old or ≥ 12 years old
2. Epilepsies associated with genetic disorders other than Dravet syndrome or CDKL5 deficiency
3. Patient has Dravet or CDKL5 genetic mutations that are NOT nonsense mutations
4. Felbatol has been initiated within the past 12 months prior to the Screening Visit
5. Patients who are currently or have participated in clinical trials in the 30 days prior to enrollment (Baseline Visit)
6. Prior or ongoing medical condition (eg, concomitant illness, psychiatric condition), medical history, physical findings, or laboratory abnormality that, in the investigator's opinion, could adversely affect the safety of the patient, makes it unlikely that the course of study drug administration or follow-up would be completed, or could impair the assessment of study results.
7. Ongoing intravenous administration of aminoglycosides or vancomycin.

Contacts and Locations

Locations

United States, New York

New York University School of Medicine

New York, New York, United States, 10016

Sponsors and Collaborators

NYU Langone Health

PTC Therapeutics

Investigators

• Principal Investigator: Orrin Devinsky, MD; NYU

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Devinsky O, King L, Bluvstein J, Friedman D. Ataluren for drug-resistant epilepsy in nonsense variant-mediated Dravet syndrome and CDKL5 deficiency disorder. Ann Clin Transl Neurol. 2021 Feb 4. doi: 10.1002/acn3.51306. [Epub ahead of print]

• Responsible Party: NYU Langone Health
• ClinicalTrials.gov Identifier: NCT02758626
• Other Study ID Numbers: 15-00426
• First Posted: May 2, 2016
• Last Update Posted: October 23, 2020
• Last Verified: October 2020

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

Additional relevant MeSH terms:

Epilepsy; Epilepsies, Myoclonic; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Epilepsy, Generalized; Epileptic Syndromes